FLUDARA

Country: Iżrael

Lingwa: Ingliż

Sors: Ministry of Health

Ingredjent attiv:

FLUDARABINE PHOSPHATE 50 MG/VIAL

Disponibbli minn:

SANOFI - AVENTIS ISRAEL LTD

Kodiċi ATC:

L01BB05

Għamla farmaċewtika:

POWDER FOR SOLUTION FOR INJ/INF

Rotta amministrattiva:

I.V

Manifatturat minn:

GENZYME EUROPE B.V., NETHERLANDS

Grupp terapewtiku:

FLUDARABINE

Indikazzjonijiet terapewtiċi:

Palliative treatment of patients with CLL refractory to other therapy. Treatment of less malignant Non-Hodgkin lymphoma of stage 3 to 4 in patients who have not responded to standard therapy with at least one alkylating agent or in whom the disease progressed during or after standard therapy. Fludara is indicated for the initial treatment of patients with B- cell chronic lymphocytic leukaemia (CLL) or after first line therapy, in patients with sufficient bone marrow reserves.

Data ta 'l-awtorizzazzjoni:

2009-02-01